Arbutus Biopharma Q1 EPS $(0.10) Beats $(0.11) Estimate, Sales $1.53M Miss $2.15M Estimate
Portfolio Pulse from Benzinga Newsdesk
Arbutus Biopharma (NASDAQ:ABUS) reported Q1 EPS of $(0.10), beating estimates by 9.09% but missed sales estimates with $1.53M, a 77.09% decrease from last year.
May 02, 2024 | 11:31 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Arbutus Biopharma reported a smaller than expected quarterly loss but missed on sales estimates, with a significant year-over-year decrease.
While the EPS beat might be seen positively, the significant miss on sales and the sharp decrease from the previous year's figures could concern investors about the company's revenue growth and operational efficiency.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100